134 related articles for article (PubMed ID: 38376107)
21. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.
Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Tueckmantel C; Cabre-Marquez JF; Wang M
Eur J Haematol; 2023 Jan; 110(1):77-87. PubMed ID: 36192847
[TBL] [Abstract][Full Text] [Related]
23. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
[TBL] [Abstract][Full Text] [Related]
24. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Tiede A; Klamroth R; Oldenburg J
Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
[TBL] [Abstract][Full Text] [Related]
25. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
26. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.
John MJ; Chakrabarti P; Apte S; Bhattacharyya M; S C; Hansen T; Kolla R; Ross C; Seth T; Siddharthan N; Abraham A
Res Pract Thromb Haemost; 2020 Nov; 4(8):1324-1330. PubMed ID: 33313471
[TBL] [Abstract][Full Text] [Related]
27. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A.
Tiede A; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Chowdary P
Haemophilia; 2022 Jan; 28(1):27-35. PubMed ID: 34562332
[TBL] [Abstract][Full Text] [Related]
28. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
Sanabria M; Álvarez Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Oldenburg J; Friedl S; Reding MT
BMJ Open; 2021 Sep; 11(9):e044997. PubMed ID: 34475142
[TBL] [Abstract][Full Text] [Related]
29. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
30. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
[TBL] [Abstract][Full Text] [Related]
31. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
[TBL] [Abstract][Full Text] [Related]
33. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
34. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
Ezban M; Vad K; Kjalke M
Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
[TBL] [Abstract][Full Text] [Related]
35. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
39. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.
Tarantino MD; Hardesty B; Metjian A; Ortel TL; Chen J; Badejo K; Ma A; Cuker A; Rajasekhar A; Friedman KD; Janbain M
Haemophilia; 2023 Sep; 29(5):1259-1268. PubMed ID: 37584309
[TBL] [Abstract][Full Text] [Related]
40. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
